Radiolabeled Biaryl Imaging Agents for Alzheimer's Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease are limited in early detection and monitoring of senile plaques and neurofibrillary tangles, as they often require histological examination and are ineffective in presymptomatic diagnosis, with existing imaging agents failing to accurately detect these markers in living patients.
Innovation Solution
Development of biaryl or bis-aromatic compounds with radiolabels, such as 18F, that specifically bind to senile plaques and neurofibrillary tangles, allowing for in vivo imaging and detection of amyloid deposits and tau aggregates in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If histological examination is used to detect senile plaques and neurofibrillary tangles, then diagnostic accuracy is improved, but the method cannot be applied for early or presymptomatic diagnosis in living patients
Solution Approach 1:
The patent replaces the mechanical histological examination process with a molecular imaging system using radiolabeled compounds. These compounds bind specifically to amyloid-beta aggregates and tau proteins in living brains, allowing detection via PET or SPECT imaging without requiring tissue extraction or histological processing. This substitution enables presymptomatic diagnosis while maintaining diagnostic accuracy.
Solution Approach 2:
The patent introduces radiolabeled imaging compounds as intermediaries between the diagnostic system and the pathological targets. These compounds specifically bind to senile plaques and neurofibrillary tangles, serving as mediators that allow indirect but accurate detection of pathological aggregates in living patients through non-invasive imaging techniques.
2Difficulty of detecting and measuring
If existing imaging agents are used to detect amyloid deposits, then some detection capability is achieved, but specificity and accuracy for early diagnosis remain insufficient
Solution Approach 1:
The patent modifies the chemical and physical parameters of imaging agents by developing radiolabeled compounds with optimized molecular structures. These compounds exhibit enhanced binding affinity and specificity for amyloid-beta aggregates and tau proteins compared to existing agents. The radiolabeling enables detection via PET or SPECT with superior sensitivity and accuracy for early diagnosis.
Solution Approach 2:
The patent creates composite imaging agents by combining radiolabeled compounds with specific molecular structures that target pathological aggregates. These composite materials integrate the detection capabilities of radiolabels with the specificity of designed ligands, achieving both high detection capability and precision for early Alzheimer's diagnosis.
3Reliability
If late stage diagnosis is performed after symptom presentation, then AD-associated pathologies can be confirmed, but the opportunity for early intervention is lost
Solution Approach 1:
The patent enables preliminary detection of Alzheimer's pathology before clinical symptoms appear. By using radiolabeled imaging compounds that bind to amyloid-beta and tau proteins, the system can identify pathological aggregates in the presymptomatic stage, allowing early intervention before significant neuronal damage occurs. This preliminary action maintains reliable pathology confirmation while eliminating diagnostic delay.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enable early and accurate diagnosis of Alzheimer's disease by specifically targeting and binding to pathological aggregates, facilitating the monitoring of disease progression and treatment efficacy.
Implementation Method 1
biaryl or bis-aromatic compounds with radiolabels, such as 18F, that specifically bind to senile plaques and neurofibrillary tangles, allowing for in vivo imaging and detection of amyloid deposits and tau aggregates in the brain
Data Source
Figure 1a
Figure 1b
Figure 2
AI summary
Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and ß-amyloid peptides are presented herein. The invention also relates to methods of imaging Aß and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disoders.